Leukemias such as chronic lymphocytic leukemia (CLL) and acute lymphoblastic leukemia (ALL) are also being targeted, with at least 40 trials focusing on CD19 as the primary target. This evidence concerns the gene CD19 and B-cell chronic lymphocytic leukemia.